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FibrosisNeuraminidase-1 (NEU1) is the sialidase responsible for the catabolism of sialoglycoconjugates in lysosomes.
Congenital NEU1 deﬁciency causes sialidosis, a severe lysosomal storage disease associated with a broad spec-
trumof clinical manifestations, which also include skeletal deformities, skeletal muscle hypotonia andweakness.
Neu1−/− mice, a model of sialidosis, develop an atypical form of muscle degeneration caused by progressive
expansion of the connective tissue that inﬁltrates the muscle bed, leading to ﬁber degeneration and atrophy.
Here we investigated the role of Neu1 in the myogenic process that ensues during muscle regeneration after
cardiotoxin-induced injury of limb muscles. A comparative analysis of cardiotoxin-treated muscles from
Neu1−/− mice and Neu1+/+ mice showed increased inﬂammatory and proliferative responses in the absence
of Neu1 during the early stages of muscle regeneration. This was accompanied by signiﬁcant and sequential
upregulation of Pax7,MyoD, and myogeninmRNAs. The levels of both MyoD and myogenin proteins decreased
during the late stages of regeneration, which most likely reﬂected an increased rate of degradation of the myo-
genic factors in the Neu1−/−muscle. We also observed a delay in muscle cell differentiation, which was charac-
terized by prolonged expression of embryonic myosin heavy chain, as well as reduced myoﬁber cross-sectional
area. At the end of the regenerative process, collagen type III deposition was increased compared to wild-type
muscles and internal controls, indicating the initiation of ﬁbrosis. Overall, these results point to a role of Neu1
throughout muscle regeneration.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Neuraminidases catalyze the removal of sialic acid residues from the
nonreducing end of glycoproteins, glycolipids, oligosaccharides, and
polysaccharides [1]. Four distinct neuraminidases, neuraminidase-1
(NEU1) through NEU4, are found in mammals. These exoglycosidases
differ in their subcellular distribution and substrate speciﬁcity: NEU1
is lysosomal; NEU2 is cytosolic; NEU3 is found at the plasmamembrane,
and NEU4 appears to be distributed in lysosomes, mitochondria, and
endoplasmic reticulum [2,3]. In mammalian cells, enzymatically active
NEU1 is found in complex with the serine carboxypeptidase protective
protein/cathepsin A and β-galactosidase [4,5]. Association with the
former is necessary for NEU1 to be correctly compartmentalized and
activated in lysosomes [6].
NEU1 deﬁciency leads to sialidosis, an autosomal recessive lyso-
somal storage disease caused by genetic mutations at the NEU1 locus-bromo-2′-deoxyuridine; CTX,
ogenase; H&E, hematoxylin and
1; NEU1, neuraminidase-1; TA,
y, University of São Paulo, 455
azil. Tel.: +55 11 30617460.on chromosome 6p21 [7]. Patients with sialidosis type-I manifest signs
of the disease mostly during the second decade of life, including pro-
gressive loss of vision with macular degeneration (cherry-red spots),
nystagmus, ataxia, seizures, and myoclonus syndrome. Patients with
sialidosis type-II suffer a very severe condition, with onset of symptoms
at birth or during the early neonatal period and reduced lifespan. Fetal
hydrops, neonatal ascites, dysmorphic Hurler-like features, dysostosis
multiplex, hepatosplenomegaly, and severe neurologic impairment
starting in the perinatal period or infancy are common manifestations
in type-II cases [7,8]. A subset of patients with sialidosis experiences skel-
etal deformities, skeletal muscle atrophy and hypotonia [9].
Neu1−/−micehave phenotypic abnormalities intermediate between
sialidosis type-I and -II, but they faithfully recapitulate the complex and
widespread biochemical and morphological changes characteristic of
the human disease [10]. Numerous studies in vitro and inmousemodels
have implicated NEU1 in fundamental biological processes that go
beyond its canonical degradative function; these include immune re-
sponse and inﬂammation [11,12], cell proliferation [13,14], and tumor
cell migration andmetastasis [1,15,16]. A primary role of NEU1 as a neg-
ative regulator of lysosomal exocytosis has been identiﬁed [17–20]. This
calcium-regulated process, which is present in virtually all cell types,
entails the recruitment of selected lysosomes to the cytoskeletal net-
work, followedby their docking at the plasmamembrane. Upon calcium
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contents extracellularly [21]. NEU1 limits the number of lysosomes
that dock at the plasma membrane by processing the sialic acids on
the lysosome-associated membrane protein 1 (LAMP1), one of its
substrates. Deﬁciency of NEU1 results in the accumulation of an
oversialylated LAMP1, which leads to exacerbated lysosomal exocytosis
in many tissues and cell types with deleterious consequences on the
integrity of the extracellular matrix and plasma membrane and overall
tissue homeostasis.
In the Neu1−/− skeletal muscle, excessive exocytosis of lysosomal
contents into the extracellular matrix has been linked to the abnormal
expansion of connective tissue, which is associated with increased
synthesis and deposition of collagen and other of its components due
to hyperproliferation of ﬁbroblasts [20]. We found that ﬁbroblasts
with exacerbated lysosomal exocytosis inﬁltrate the adjacent muscle ﬁ-
bers, which gradually become fragmented, vacuolated, and ultimately
degenerate, leading to progressive atrophy [20]. Although we know
that muscular degeneration is part of the pathogenesis of sialidosis in
themousemodel, no one has investigated howmyogenesis andmuscle
regeneration occur in the context of NEU1 deﬁciency in vivo. However,
in vitro studies with C2C12 myoblasts have suggested that NEU1 ex-
pression is regulated by transcription factors, like MyoD, that are in-
volved in skeletal muscle regeneration and myogenesis [22,23]. In
addition, NEU1 expression appears to be strictly controlled during the
early stages of C2C12 cell differentiation, because Neu1 overexpression
during the course of differentiation suppresses myogenin and myosin
heavy chain expression, thus disrupting the differentiation process [23].
Cardiotoxin (CTX) injection is among the easiest andmost reproduc-
ible methodologies to induce muscle regeneration (reviewed in [24]).
CTX causes depolarization and disruption of plasma membranes of
muscular cells; thus it induces local necrosis and regeneration [24].
Right after muscular damage, neutrophils and macrophages inﬁltrate
the tissues and myogenic precursor cells start to proliferate [24]. Differ-
ent myogenic regulatory factors (among them MyoD, Myf5, myogenin
and MRF4) are successively expressed in the course of muscle regener-
ation. Furthermore, immature variants of myosins, initially embryonic
myosin heavy chain, are progressively substituted by mature forms of
myosin (fast and/or slow isoforms). These events stimulate the differen-
tiation of muscle precursor cells, which fuse with themselves and with
injured ﬁbers to form new skeletal muscle ﬁbers [24].
Here, we evaluate the course of muscle regeneration after CTX-in-
duced injury of wild-type or Neu1−/−muscle and assess the extent of
cell proliferation, the inﬂammatory response, the grade of maturation
of myoﬁbers, and the deposition of extracellular matrix at different
stages of the regenerative process that occurs after an injury.
2. Material and methods
2.1. Animals
Male Neu1−/− andwild-type (Neu1+/+) mice (FVB/NJ background),
aged 8 weeks, were used in this study. Neu1−/−mice were previously
generated by targeted disruption in the Neu1 locus [10]. Animals were
housed in the animal facility, under controlled temperature, humidity,
and lighting (12 h light/dark cycle). Food and water were provided ad
libitum. All procedures in mice were approved by the Animal Care and
Use Committee of the School of Medicine of the University of São
Paulo and followed NIH guidelines.
2.2. Induction of necrosis and regeneration of muscle
Cardiotoxin (CTX; Sigma) puriﬁed fromNajamossambicamossambica
was used to induce local necrosis after intraperitoneal anesthesia with
5 mg/kg of diazepam and 100 mg/kg of ketamine. CTX (10 mM) was
injected in the proximal tendon region of the right tibialis anterior (TA)
muscle toward the distal tendon; the left TA muscle was used as aninternal control (CTR). CTX-injected Neu1−/− and Neu1+/+ mice (n =
5 per group) were euthanized at day 1, 3, 5, 7, 10, 14, 21, or 28 after
CTX administration. Right TA muscles from untreated Neu1−/− and
Neu1+/+mice (2months old, n=5per genotype)were used as a control
group (day 0). TA muscles were dissected, snap-frozen in isopentane
cooled in liquid nitrogen and stored at−80 °C until use.2.3. Histology
Transverse sections (7 μm) of the frozen TA muscles were cut on a
cryostat (Leica CM3000). The sections were stained with hematoxylin
and eosin (H&E) for overall morphologic assessment and examined
under a light microscope (Olympus AX70). Cross-sectional areas of TA
ﬁbers were measured using ImageJ software (NIH Software). At least
200 ﬁbers were considered per animal, and the mean ﬁber area was
calculated for each muscle.2.4. Immunohistochemistry
Frozen sections were thawed, and endogenous peroxidase activity
was quenched with 0.3% hydrogen peroxide in phosphate-buffered
saline (PBS) for 30 min. The sections were blocked with 1% bovine
serum albumin (BSA), 0.5% Tween-20, and 10% normal goat serum in
PBS for 1 h and incubated overnight at 4 °C with rat anti-collagen III
(1:100 dilution) (ACRIS Pharmaceuticals; BM4018), rat anti-LY6G
(1:50 dilution) (BD Biosciences; 553124) and rat anti-CD11b (1:100
dilution) (BD Biosciences; 557395); all antigenswere diluted in blocking
solution. On the next day, the sections were incubated with biotinylated
anti-rat secondary antibody for 1 h at room temperature and then
reacted with ABC reagent (Vector Laboratories) for 1 h at room temper-
ature. The sections were incubated with 3,3′-diaminobenzidine sub-
strate for 2 min and then washed in distilled water to stop the reaction.
They were then counterstained with hematoxylin and examined under
a light microscope.2.5. Immunoﬂuorescence microscopy
Frozen sections were ﬁxed in acetone for 20 min and blocked with
2% BSA and 10% normal serum in PBS for 30min. Sectionswere incubat-
ed with AfﬁniPure Fab Fragment Goat Anti-Mouse IgG (H+ L) (Jackson
ImmunoResearch; 115-007-003) in PBS (1:10 dilution) for 1 h at room
temperature and incubated overnight at 4 °C with anti-embryonic my-
osin heavy chain (Developmental Studies Hybridoma Bank; F1.652) in
blocking solution (1:20 dilution). The next day, the sections were
blocked for 10 min and incubated with FITC–AfﬁniPure Goat Anti-
Mouse IgG (H + L) (Jackson ImmunoResearch; 115-095-003) in
blocking solution (1:200 dilution) for 1 h at room temperature. Slides
were mounted with Vectashield mounting medium/DAPI (Vector; H-
1200). Control sections were incubated with secondary antibody only.
The slides were examined under a ﬂuorescence microscope (Olympus
AX70).2.6. BrdU
Mice euthanized on day 3, 5, or 7were also injected intraperitoneally
with 160 mg/kg 5-bromo-2′-deoxyuridine (BrdU; Sigma). Mice were
euthanized 6 h after injection, and the muscles were processed as
described in Sections 2.3–2.5. For the immunoﬂuorescence staining,
an extra step was added to the protocol: A 30-min treatment with
1.5 M HCl at room temperature prior to incubation with the BrdU
primary antibody (1:100 dilution) (Sigma; B8434). The number of
BrdU+nuclei in eachmusclewas quantiﬁed, and themeanwas calculat-
ed per animal.
Fig. 1.Neu1mRNAexpression is temporally regulated during skeletalmuscle regeneration
after CTX-induced injury. *p b 0.05 and **p b 0.01 indicate differences in the level of Neu1
expression in regenerating muscle compared to that in untreated control muscle (day 0);
Mann–Whitney test (n = 5).
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Fig. 2. Bound sialic acid (SA) content in TA muscles. **p b 0.01 indicates differences in the
amount of bound sialic acid in Neu1+/+ and Neu1−/−; Mann–Whitney test (n = 3).
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Total RNA was isolated using TRIzol Reagent (Life Technologies)
and treated with DNAse I (Applied Biosystems/Ambion) according
to the manufacturer's instructions. First-strand cDNA was tran-
scribed using 1 μg total RNA with TaqMan Reverse Transcription
Reagents (Life Technologies). RT-PCR was executed with Maxima
SYBR Green PCR/ROX qPCR Master Mix (Thermo Scientiﬁc) on a
StepOne Plus machine (Applied Biosystems). The primers used are
summarized in Suppl. Table 1. The data obtained were subjected
to calculations of relative expression and normalized using GAPDH
expression.
2.8. Western blotting
For Western blot analysis, TA muscle fragments were homogenized
in 5 volumes of RIPA buffer (10% SDS, 70 mmol/L Tris–HCl (pH 6.7),
10 mmol/L EDTA, 5% β-mercaptoethanol), and protease inhibitors
(Roche) using a Dounce homogenizer. The homogenates were centri-
fuged at 13,000 ×g for 5 min at 4 °C, and the supernatants were trans-
ferred to new microtubes. The protein concentrations were determined
by absorbance (A = 595) using a BSA solution standard. Samples
(25 μg) were subjected to electrophoresis on SDS-PAGE gels (10% or
12%) and transferred to PVDFmembranes. Themembraneswere blocked
with 10% nonfat milk in Tris-buffered saline containing 0.05% Tween-20
(TBS/T) for 20 min and incubated with mouse anti-myogenin (Sigma;
M5815, 1:2000 dilution) and mouse anti-MyoD (BD Pharmingen;
554130, 1:3000 dilution) overnight at 4 °C. Themembraneswerewashed
with TBS/T and incubated with horseradish peroxidase-conjugated goat
anti-mouse antibody (1:6000 dilution) for 1 h. Theywere then incubated
with Western Lightning Chemiluminescence Reagent Plus (PerkinElmer
Life Science) for 1min and thendeveloped against X-rayﬁlms. Coomassie
Brilliant Blue was used to visualize protein loading. The membranes
were digitalized, and total protein was quantiﬁed using ImageJ 1.43u
software.
2.9. Sialic acid assay
Total (bound and free) sialic acid content was obtained using an
EnzyChrom Sialic Acid Assay Kit (BioAssay Systems). TA muscle lysates
were either treated with a hydrolysis reagent (1 h at 80 °C) to release
bound sialic acid content or used untreated to measure free sialic acid.
The samples were placed in black clear-bottom 96-well plates, probed
with dye reagent and the enzyme provided by the kit. The amount of si-
alic acid of the samples was measured in excitation wavelength of
535 nm and emission wavelength of 595 nm, and compared to a 0 to
500 pmol sialic acid standard curve.
2.10. Statistical analyses
Statistical analyses were performed using a 2-way ANOVA test
followed by either the Bonferroni post-test (Gaussian distribution)
or Mann–Whitney test (non-Gaussian distribution). The results are
presented as means ± standard deviations. Signiﬁcant variations were
accepted when p ≤ 0.05. Statistical analyses were performed using
GraphPad Prism 5 software for Windows (GraphPad Software).
3. Results
3.1. Neu1 expression is upregulated during the early stages of muscle
regeneration
We ﬁrst assessed the pattern of Neu1 mRNA expression during
muscle regeneration after local CTX injection into Neu1+/+ TA mus-
cles by using RT-qPCR. Neu1 expression was signiﬁcantly increased
at day 1 after injury and remained highly expressed until day 10.Normal expression levels resumed at day 14, indicating that Neu1
is upregulated mainly during the ﬁrst stages of muscle regeneration
(Fig. 1).
3.2. Neu1−/−muscles have higher content of bound sialic acid
Neu1 upregulation during regeneration as well previous data about
the effects of Neu1 deﬁciency in skeletal muscles [20], lead to the
hypothesis that Neu1 activity is important for the normal physiology
of this tissue. In order to verify the sialylation pattern in skeletal
muscles, we compared the amount of bound sialic acid in Neu1+/+
and Neu1−/− in TA muscles, conﬁrming an increase of sialylation in
Neu1−/−muscles (Fig. 2).
3.3. CTX-injured Neu1−/− skeletal muscle displays a dystrophic phenotype
at the end of the regeneration process
The myoﬁber areas of the Neu1−/− TA muscle were, in general,
smaller than those of the Neu1+/+ TA muscle at all time points after
CTX injection (Fig. 3). In fact, theNeu1+/+myoﬁbers regained their nor-
mal size before or around day 28 of regeneration, whereas the Neu1−/−
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Fig. 3. The cross-sectional area of myoﬁbers from Neu1+/+ (white bars) or Neu1−/− (black
bars) muscles during regeneration after CTX-induced injury. *p b 0.05, **p b 0.01, and
***p b 0.001 indicate differences in the cross-sectional area of myoﬁbers in regenerating
muscles compared with that in untreated control muscle (CTR); #p b 0.05 indicates differ-
ences between the cross-sectional area ofNeu1−/−myoﬁbers and that ofNeu1+/+myoﬁbers
on the same day of regeneration; two-way ANOVA with Bonferroni post-test (n = 5).
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indicating an impaired or delayed regeneration process (or trophism)
of the Neu1−/−muscles.
To determine whether any morphologic changes occurred after CTX
injection and whether those changes differed in the Neu1−/− versus
Neu1+/+ muscles, we examined cross sections of the injured muscles
stained with H&E (Fig. 4). After the CTX injection, both Neu1+/+ and
Neu1−/− TA muscles showed widespread damage of the ﬁbers. During
the ﬁrst 3 days posttreatment, the muscles showed areas with promi-
nent necrosis (pale and fragmented cytosol) and increased cellularity
(Fig. 4). After day 5, the Neu1+/+ TA muscle exhibited small, round, re-
generative muscle ﬁbers with centralized nuclei (myotubular aspect).
The excessive connective tissue seen at day 3 was replaced by growing,
newly formed myoﬁbers at day 7 (Fig. 4). Full histologic reorganization
in the injured Neu1+/+ muscle occurred between day 14 and day 28Fig. 4.H&E staining of transverse sections ofNeu1+/+ andNeu1−/− TAmuscles during regenera
on days 1 and 3 postinjection, and regenerative ﬁbers with centralized nuclei (arrows) arise
deposition of extracellular matrix components and smaller muscle ﬁbers. Scale bars = 40 μm(Fig. 4). In contrast, Neu1−/− muscle showed expanded endomysium
and perimysium spaces (connective tissue) throughout the regenera-
tion period. Immunostaining for collagen III at day 14 showed increased
expression of this collagen in the endomysium space (Fig. 5A). Collagen
III levels remained high in the Neu1−/− regenerated muscle but were
normalized around day 21 in the Neu1+/+ muscle (Fig. 5A). Although
some regions of the regenerating Neu1+/+ muscle had an increased
number of ﬁbroblasts, similar areas in the Neu1−/−muscle displayed a
dramatic expansion of the connective tissue with increased cellularity
at day 28 (Fig. 5B).
3.4. The expression of MyoD and myogenin is altered and myoﬁber
maturation is delayed in Neu1−/−muscle during regeneration
We next evaluated the mRNA and protein expressions of MyoD
and myogenin to determine whether the Neu1 deﬁciency inﬂuenced
muscle maturation in the earlier and later stages of skeletal muscle
regeneration. In Neu1+/+ muscle, MyoD mRNA expression peaked at
day 3 after injury and rapidly diminished from day 5 onward (Fig. 6A).
MyoD mRNA had a similar expression proﬁle in CTX-injured Neu1−/−
muscle, but its expression levels were signiﬁcantly higher than in
Neu1+/+ muscle from day 3 to day 7 (Fig. 6A). In contrast, the level of
MyoD protein was signiﬁcantly lower in Neu1−/−muscle at day 5 and
day 7 than it was in Neu1+/+ muscle, which remained high until day 7
(Fig. 6B). From day 7 on, MyoD levels were very low in all groups and
statistically equal to day 0 in both genotypes, and there were no differ-
ences between MyoD expression in Neu1+/+ and Neu1−/− muscles
(Suppl. Fig. 1).
As expected, myogenin mRNA levels in injured Neu1+/+ muscle
peaked at day 7 and day 14, about 3 days later than MyoD, and the
protein was still overexpressed at day 21 (Fig. 6C–D).MyogeninmRNA
levels were signiﬁcantly higher in Neu1−/−muscle than in the Neu1+/+
muscle only at day 7 but declined to the levels of the Neu1+/+ muscle
at day 14 and day 21 (Fig. 6C). Similarly to MyoD, myogenin protein
levels were reduced at day 7, a time whenmyogeninmRNA levels were
the highest (Fig. 6D). These results suggest that these myogeniction after CTX-induced injury (n=5). Degenerating ﬁbers (asterisks) are noted, especially
on day 5. A delay in muscle reorganization is noted in the Neu1−/−mice, with excessive
and apply to all images.
Fig. 5. Immunohistochemical staining for collagen III in Neu1+/+ and Neu1−/− TAmuscles during late stages of regeneration (n= 5). Labeling was more intense after day 14 in Neu1−/−
muscles (A), and greater ﬁbroblast inﬁltrates can be seen in these mice on day 28 (B). Scale bar = 100 μm and applies to all images.
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muscle regeneration.
The expression of transcription factors can directly inﬂuence the
levels of muscle-speciﬁc proteins; therefore, we also investigated the
expression of embryonic myosin heavy chain via indirect immunoﬂuo-
rescence. Embryonic myosin heavy chain was expressed at high levels
in both groups of CTX-injured muscles at day 5 of regeneration. Never-
theless, the highest expression of embryonic myosin heavy chain
occurred in the Neu1−/−muscle and persisted for a longer period after
injury, especially in smaller ﬁbers, which indicated a delay in the matu-
ration of the myoﬁbers (Fig. 7).
3.5. Atrogin-1 andMuRF-1 genes are upregulated at days 5 and 7 of muscle
regeneration in Neu1−/−muscles
Because of discrepancies between gene and protein expression in
Neu1−/−muscles,we reasoned that protein degradation could be occur-
ring. The ubiquitin–proteasome system is an important mechanism to
degrade proteins in skeletal muscles. This system requires the interac-
tion of three enzymes (E1, E2 and E3) to cause the ubiquitination of
proteins, and its subsequent degradation [25]. Atrogin-1 and MuRF-1
are the mostly encoded E3 ligases when the ubiquitin–proteasome
system is active in muscles [26,27]. For this reason, we decided to
study the gene expression of atrogin-1 and MuRF-1. In normal mice,atrogin-1 and MurF-1 are upregulated at day 7; in Neu1−/− muscles,
both atrogenes were upregulated at days 5 and 7 of skeletal muscle re-
generation. Moreover, these genes are overexpressed in Neu1 deﬁcient
muscles, when compared to wild-type muscles (Fig. 8).
3.6. Abnormally increased cell proliferation in CTX-injured Neu1−/−
skeletal muscles
We next assessed the inﬂuence of Neu1 deﬁciency on cell prolifera-
tion by monitoring BrdU incorporation at days 3, 5, and 7 of skeletal
muscle regeneration (Fig. 9A). Although the pattern of proliferation
was similar between Neu1−/− and Neu1+/+ muscles, the number of
BrdU+ nuclei was signiﬁcantly higher in the Neu1−/−muscle at day 5
and day 7 (Fig. 9A). This result suggests that deﬁciency of Neu1 affects
the proliferative status of cells during the early stages of muscle
regeneration.
Considering that different cell types (e.g., satellite and inﬂammatory
cells) are recruited or activated at the site of injury during early regen-
eration, we tested the expression of Pax7, a marker of satellite cells, be-
tween day 0 and day 7. The expression of Pax7was higher in the injured
Neu1−/− muscle than in the control muscle throughout the course of
the experiments (Fig. 9B). These ﬁndings suggest that the increased
cell proliferation in the Neu1−/−muscle after injury can be contributed
to not only ﬁbroblasts but also satellite cells.
Coomassie brilliant blue Coomassie brilliant blue
Day 3
Neu1+/+ Neu1-/-
Day 5
Neu1+/+ Neu1-/-
Day 7
Neu1+/+ Neu1-/-
Day 7
Neu1+/+ Neu1-/-
Day 14
Neu1+/+ Neu1-/-
Day 21
Neu1+/+ Neu1-/-
A
B
C
D
Fig. 6. The expression of MyoD and myogenin mRNA (A and C) and proteins (B and D) during skeletal muscle regeneration in Neu1+/+ (white bars) and Neu1−/− (black bars) mice.
Western blots of MyoD (45 kDa) andmyogenin (25 kDa) represent the experimental groups of both genotypes (n= 5). *p b 0.05 and **p b 0.01 indicate differences in the level of expres-
sion compared with that in the untreated control muscle (day 0); #p b 0.05 and ##p b 0.01 indicate differences between the level of mRNA or protein expression inNeu1−/−muscle and
that in Neu1+/+ muscle on the same day of regeneration; Mann–Whitney test (n = 5).
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We analyzed the inﬂammatory response to CTX-induced injury by
immunohistochemical staining of neutrophils and macrophages. In
Neu1−/− and Neu1+/+ muscles, the neutrophils were comparable until
day 3 after injury (Fig. 10A). At day 5, a few neutrophils remained at
the site of injection in the Neu1+/+ muscles, but they were no longer
detected at day 10. In the Neu1−/− skeletal muscle, neutrophils were
no longer present by day 5 (Fig. 10A), which indicated a reduced neu-
trophilic response in the Neu1−/−mice.
Macrophage inﬁltration was detected from day 1 to day 10 after
CTX-induced injury (Fig. 10B). However, in the Neu1+/+ muscle the
highest number of CD11b+ cells was seen at day 5 and declined at day10. In contrast, in the Neu1−/−muscle an increased number of macro-
phageswas seen until day 10 (Fig. 10B), suggesting a prolonged inﬂam-
matory response in the Neu1−/−muscles.
The analysis of CD11b mRNA conﬁrmed higher expression of this
marker in the Neu1−/− skeletal muscle throughout the regeneration
period (Fig. 10C). The peak of CD11b expression was around day 3,
and expression returned to normal levels about day 10 in both groups.
4. Discussion
In a previous studywith 11 patientswith sialidosis, mutant Neu1 re-
sidual activity was related with the clinical severity of the disease [9].
This study included two patients with muscular commitment; both of
Fig. 7. Indirect immunoﬂuorescence of embryonicmyosin heavy chain inNeu1+/+ orNeu1−/−muscles during regeneration after CTX-induced injury (n=5). The expression of embryonic
myosin heavy chain persisted longer in Neu1−/−muscles, especially in ﬁbers with a smaller diameter. Scale bar = 40 μm and applies to all images.
A
1761J.C. Neves et al. / Biochimica et Biophysica Acta 1852 (2015) 1755–1764them had nucleic acid substitutions in exons 4 and 5, resulting in single
amino acid substitutions (Arg294Ser in patients 1 and 2; Leu231His in
patient 1, and Gly218Ala in patient 2). This study also described that
sialidosis has different degrees of penetrance [9], which could explain
why only a subset of patients present muscular symptoms. It is notA
B
Fig. 8. Atrogin-1 (A) and MuRF-1 (B) mRNA expression at days 5, 7 and 10 of skeletal
muscle regeneration in Neu1+/+ (white bars) and Neu1−/− (black bars) TA muscles.
**p b 0.05 indicates differences between gene expression of CTX-injured muscles and
untreated control muscle for each genotype (day 0); #p b 0.05 and ##p b 0.01 indicate
differences between gene expression in Neu1−/− and Neu1+/+ muscles on the same day
of regeneration; Mann–Whitney test (n = 5).
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Fig. 9. Cell proliferation during the early stages of muscle regeneration after CTX-
induced injury (n = 5). (A) Neu1−/−muscles (black bars) had more BrdU+ nuclei than
did Neu1+/+ muscles (white bars), indicating an elevated proliferative response.
**p b 0.01 and ***p b 0.001 indicate differences between Neu1−/− muscle and Neu1+/+
muscle on the same day of regeneration; two-way ANOVA with Bonferroni post-test.
(B) Pax7 mRNA expression was elevated in both genotypes throughout regeneration.
*p b 0.05 indicates differences between the levels of Pax7 expression and that of untreated
control muscle (day 0); #p b 0.05 indicates differences between the levels of Pax7 expres-
sion inNeu1−/−muscle and that in theNeu1+/+muscle on the same day of regeneration;
Mann–Whitney test (n = 5).
Neu1+/+ Neu1-/-Neu1+/+ Neu1-/-
Day 10
Day 5
Day 3
Day 1
C
B
Day 10
Day 5
Day 3
Day 1
A
Fig. 10. Inﬂammation during muscle regeneration in Neu1+/+ and Neu1−/−mice (n = 5). Immunohistochemical staining for neutrophils (A) and macrophages (B) shows discrepancies
between the genotypes, as conﬁrmed by CD11bmRNA expression analysis in Neu1+/+ (white bars) and Neu1−/− (black bars) muscles (C). Scale bar = 40 μm and applies to all images.
*p b 0.05 and **p b 0.01 indicate differences compared with the level of expression of CD11b in untreated control muscle (day 0); #p b 0.05 indicates the differences between the levels of
CD11b expression in Neu1−/− and Neu1+/+ muscles on the same day of regeneration; Mann–Whitney test.
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cle of patients with sialidosis, because no biopsy has been obtained so
far. This reality reinforces the importance of our animalmodel to under-
stand muscle physiology in different situations.
The aim of this study was to determine the effect of Neu1 deﬁciency
on skeletal muscle regeneration in vivo after CTX injection. Overall, our
ﬁndings indicated that losingNeu1 function affects important aspects of
skeletal muscle regeneration, including the inﬂammatory response,
myoﬁber maturation, and extracellular matrix reconstitution. Although
the molecular mechanisms underlying the altered regenerative process
in the Neu1-deﬁcient mice are still under investigation, the results of
this study reiterate the importance of controlling the sialic acid content
of target NEU1 substrates for skeletal muscle physiology [20].
Here we showed that Neu1 deﬁciency is associated with the expan-
sion of the perimysium and endomysial spaces during skeletal muscle
regeneration, resulting in a dystrophic phenotype. In skeletal muscle,
the interplay between the extracellularmatrix and individual muscle ﬁ-
bers is crucial for the normal function and integrity of the tissue. In
addition to providing mechanical support, the extracellular matrix andthe basement membrane/basal lamina, in particular, function as a scaf-
fold during muscle regeneration. Disturbing any of these components
may adversely affect muscle strength and integrity and result in muscle
disease or defective skeletal muscle regeneration [28,29]. In Neu1−/−
mice, muscle tissue undergoes progressive degeneration that is associ-
ated with profound alterations in the extracellular matrix components
and inﬁltration of the muscle bed by connective tissue [20]. Many
of these abnormalities can be attributed to increased proliferation of
ﬁbroblast-like cells, abnormal deposition of collagen ﬁbers, and en-
hanced proteolytic activity in the extracellular matrix. These features
are linked, at least in part, to excessive Neu1-dependent lysosomal exo-
cytosis [17,20].
LAMP1, a substrate of Neu1, is important for the docking of lyso-
somes to the PM [17]. In the absence of Neu1, oversialylated LAMP1
has a longer half-life, and this increases the number of lysosomes poised
to dock at the PM and engage in lysosomal exocytosis [17]. The down-
stream effect is the enhanced release of catalytically active proteases
and glycosidases extracellularly, a phenomenon that affects theprocess-
ing of cell-surface proteins and extracellular matrix components [17].
1763J.C. Neves et al. / Biochimica et Biophysica Acta 1852 (2015) 1755–1764These authors also demonstrated an inverse correlation between the
levels of residual NEU1 activity and lysosomal exocytosis in ﬁbroblasts
of patients with sialidosis and different clinical phenotypes. This feature
is fully recapitulated in mouse ﬁbroblasts isolated from Neu1−/− skele-
tal muscle, indicating the involvement of this aberrant process in the
development of the muscle phenotype [20].
In this study, we showed that in addition to basal muscular atrophy,
regenerating Neu1−/− muscle ﬁbers have an impaired growth rate,
maintaining a higher degree of atrophy than that of the uninjured
Neu1−/− muscle ﬁbers, especially during the late stages of muscle re-
generation. We previously showed an increased release of cathepsins
via lysosomal exocytosis into the extracellular matrix of the Neu1−/−
muscle connective tissue and activation of matrix metalloproteinases
[20]. Both of these events contribute to the atrophic phenotype in the
Neu1-deﬁcient muscle and may explain the muscle hypotonia in pa-
tients with sialidosis.
In the regeneratingNeu1−/−muscle ﬁbers, embryonicmyosin heavy
chain was expressed during the later stages of regeneration, suggesting
delayed maturation. In addition, the expression of myogenic factors
(MyoD and myogenin) was abnormal in the Neu1−/− regenerating
muscle, which indicated that Neu1 deﬁciency induces changes in the
expression proﬁles of myogenic transcription factors during muscle
regeneration. A previous study in C2C12 myoblasts in vitro suggested
the involvement of Neu1 in the early stages of myogenesis, possibly
under the regulation of MyoD [23]. The authors also showed that in
the C2C12 myoblasts the activity of Neu1 is highly and temporally reg-
ulated duringmyogenesis. They postulated that increased Neu1 expres-
sion in myoblasts results in the desialylation of surface molecules,
leading to the inhibition of differentiation and cell fusion with reduced
expression of myogenin and myosins [23]. In agreement with these
in vitro studies, we now show that in wild-type mice the expression
of Neu1was high from day 1 to day 10 after CTX-induced injury.
Usually, skeletalmuscle is able to adapt to several physiological condi-
tions through cell and protein turnover [30]. Atrogin-1 and MuRF-1 are
very important genes that participate in this process [26,27], but we
found that these genes were upregulated at days 5 and 7 of regeneration
in Neu1−/−muscles, compared to normal muscles. Indeed, atrogin-1 is
recognized as the E3 ligase responsible for MyoD degradation [31],
which could explain the low levels of MyoD in these mice, even with up-
regulated gene. Increased expression of atrogin-1 and reduced expression
ofmyogenin had previously been linked to a model of skeletal muscle at-
rophy [32]. In turn, MuRF-1 controls the half-life of important structural
muscle proteins [33–35], including myosin heavy chains [33,34].
Neu1 is involved in cell proliferation [15]. In arterial smooth muscle
cells, Neu1 alters the cellular responsiveness to mitogenic ligands and is
a negative regulator of cell proliferation.We have shown that Neu1 reg-
ulates ﬁbroblast proliferation and thus extracellular matrix remodeling
in skeletal muscle most likely via increased lysosomal exocytosis [20].
Results from our BrdU experiment indicated that Neu1 deﬁciency
increases cell proliferation during skeletal muscle regeneration. We
propose that not only ﬁbroblasts but also satellite cells are affected, con-
sidering the increased expression of Pax7.
The inﬂammatory process is an important step duringmuscle regen-
eration [24], thus we tested neutrophil and macrophage responses at
different times after muscle injury. We noticed that the neutrophil
response in Neu1-deﬁcient muscle was reduced than that in wild-type
muscle at day 3 after injury, and the macrophage response persisted
later than day 10. These ﬁndings indicate that Neu1 deﬁciency affects
the inﬂammatory response after muscle injury. Besides, studies have
demonstrated the involvement of the sialic acid and NEU1 activity in
the regulation of the inﬂammatory response [36,37].
Normally, the inﬂammatory response following muscle injury initi-
ates with the recruitment of neutrophils, which scavenge dead cells
and are found in injury sites only a few hours after injury [24,38,39].
About 24 h after injury, macrophages are attracted to the site of the
injury by proinﬂammatory neutrophils [24,38,39]. Macrophages areresponsible for the elimination of cell debris and begin the myogenic
process [24]. Oversialylation in plasma membrane receptors appears
to affect the adhesion andmigration of neutrophils [36]. This feature in-
dicates the possible mechanism related to the diminished neutrophilic
reaction we observed. In turn, oversialylation reduces macrophagic
phagocytic capacity [37]. The persistence of these cells at the injury
sites we found would compensate the phagocytic defect and ensure
downstream events in regeneration [40].
Our ﬁndings suggest that Neu1 is important for normal muscle re-
generation. Additional studies are needed to elucidate the physiological
processes in muscle that depend on the correct expression of NEU1 and
may further clarify the involvement of lysosomes and themetabolismof
sialic acid in the pathophysiology of muscle diseases.
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